These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 11642615)

  • 1. Induction and direction of immune responses by vaccine adjuvants.
    Schijns VE
    Crit Rev Immunol; 2001; 21(1-3):75-85. PubMed ID: 11642615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunity in response to particulate antigen-delivery systems.
    Storni T; Kündig TM; Senti G; Johansen P
    Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine adjuvant technology: from theoretical mechanisms to practical approaches.
    Schijns VE; Tangerås A
    Dev Biol (Basel); 2005; 121():127-34. PubMed ID: 15962475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New understanding of immunological mechanisms.
    Saalmüller A
    Vet Microbiol; 2006 Oct; 117(1):32-8. PubMed ID: 16701965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine protocols for enhanced immunogenicity of exogenous antigens.
    Heit A; Busch DH; Wagner H; Schmitz F
    Int J Med Microbiol; 2008 Jan; 298(1-2):27-32. PubMed ID: 17888726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomaterials as vaccine adjuvants.
    Jones KS
    Biotechnol Prog; 2008; 24(4):807-14. PubMed ID: 19194892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New generation of mucosal adjuvants for the induction of protective immunity.
    Yuki Y; Kiyono H
    Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell targeted immune enhancement yields effective T cell adjuvants.
    Naylor PH; Hadden JW
    Int Immunopharmacol; 2003 Aug; 3(8):1205-15. PubMed ID: 12860176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulating vaccine responses with dendritic cells and Toll-like receptors.
    Pulendran B
    Immunol Rev; 2004 Jun; 199():227-50. PubMed ID: 15233738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Starch microparticles as vaccine adjuvant.
    Rydell N; Stertman L; Sjöholm I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):807-28. PubMed ID: 16296780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fully mobilizing host defense: building better vaccines.
    Raychaudhuri S; Rock KL
    Nat Biotechnol; 1998 Nov; 16(11):1025-31. PubMed ID: 9831030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains.
    Ferrone CR; Perales MA; Goldberg SM; Somberg CJ; Hirschhorn-Cymerman D; Gregor PD; Turk MJ; Ramirez-Montagut T; Gold JS; Houghton AN; Wolchok JD
    Clin Cancer Res; 2006 Sep; 12(18):5511-9. PubMed ID: 17000687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen delivery for cross priming via the emulsion vaccine adjuvants.
    Shen SS; Yang YW
    Vaccine; 2012 Feb; 30(9):1560-71. PubMed ID: 22230588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mediastinal lymph node CD8alpha- DC initiate antigen presentation following intranasal coadministration of alpha-GalCer.
    Ko SY; Lee KA; Youn HJ; Kim YJ; Ko HJ; Heo TH; Kweon MN; Kang CY
    Eur J Immunol; 2007 Aug; 37(8):2127-37. PubMed ID: 17615581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New horizons in adjuvants for vaccine development.
    Reed SG; Bertholet S; Coler RN; Friede M
    Trends Immunol; 2009 Jan; 30(1):23-32. PubMed ID: 19059004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine adjuvant technology: from mechanistic concepts to practical applications.
    Degen WG; Jansen T; Schijns VE
    Expert Rev Vaccines; 2003 Apr; 2(2):327-35. PubMed ID: 12899582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jump-starting the immune system: prime-boosting comes of age.
    Woodland DL
    Trends Immunol; 2004 Feb; 25(2):98-104. PubMed ID: 15102369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.